Atopic dermatitis (AD) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription AD treatment, and systemic immunomodulators may be used to treat topical-refractory cases, although risk-averse pediatricians may avoid more-potent medications. Recent entrants from Pfizer (i.e., Eucrisa) and Sanofi/Regeneron (i.e., Dupixent) offer a new, nonsteroidal topical option and a biologic for topical-refractory adult patients, respectively. This content explores how new therapies have fared in pediatric patients and provides context for new players seeking to capitalize on the unmet needs in AD.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Longitudinal patient-level claims data analysis
KEY DRUGS COVERED
Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids
KEY ANALYSIS PROVIDED